Singer Capital Markets was delighted to act as Nominated Adviser and Joint Broker to Verici plc on its c.£6 million Placing and Subscription.
Verici Dx plc is an immuno‑diagnostics company that develops and commercializes AI‑enhanced RNA signature‑based tests (Clarava, Tutivia, and Protega) to assess immune response and personalised risk in kidney transplant patients.
Ticker: VRCI
Market Cap: £1.46 million*
Website: Click here
*As at 24th July 2025
| Investment Banking | |||
|---|---|---|---|
 Phil Davies Managing Director,Investment Banking Email | Call |
 Sam Butcher Assistant Director,Investment Banking Email | Call |
||
| Research & Sales | |||
|---|---|---|---|
 Karl Keegan Head of Research Email | Call |
 Edward Sham Research Analyst Email | Call |
 Jonathan Dighe Equity Sales Email | Call |
 Rhys Williams Equity Sales Email | Call |
| Investor Relations | |||
|---|---|---|---|
 Lisa Alarcon Investor Relations Email | Call |
|||
Let’s Talk
If you’re looking for more information about any of our services, or if you can’t find what you’re looking for directly on our site, please do not hesitate to contact us.
